A few years ago, former “Three’s Company” star Suzanne Somers embarked on a new career: She became a proponent of bioidentical hormones, which she describes as safe and natural therapies for menopausal women. She wrote three bestselling books on the topic, “The Sexy Years,” “Ageless” and “Breakthrough.” And to cap it all off, she will appear in a movie–titled “Suzanne Somers’ Breakthrough Tour,” which will show in some movie theaters on November 4 and November 9.
Read more here.
That headline got your attention, didn’t it? It caught my eye, too, especially when I saw the words “anti-aging ice cream” on the websites of well-known journalism outlets like Allure Magazine and Fox New York. This so-called news emanated from a deal that consumer-products giant Unilever (parent company of Ben & Jerry’s) signed recently with a Silicon Valley company called Ampere Life Sciences.
Read more about what I discovered on my quest to find anti-aging ice cream.
Acai
Way back in January 2009, the Better Business Bureau issued a warning to consumers to beware of online offers for free trials of acai berry–one of the many products sold on the Web that purports to promote weight loss and halt aging. Turns out many of the so-called free trials weren’t free at all–they actually hooked unsuspecting shoppers into expensive monthly shipments of acai juice or supplements. Since then, many consumer protection organizations have issued similar warnings. And last year, Oprah Winfrey and her on-air doctor Mehmet Oz sued 50 Internet retailers for improperly using their names and likenesses to advertise acai and other supplements.
But as I learned recently, these offers are still rampant on the Internet. Read more at HuffPo.
I am now blogging on aging for the Huffington Post. Here’s a taste of my first item:
An academic study with a provocative title landed in my inbox the other day. It’s called “Deal or No Deal: Hormones and the Mergers and Acquisitions Game,” and in it, two finance professors from the University of British Columbia argue that CEOs with high testosterone levels are likely to act recklessly in mergers and acquisitions. Testosterone-laden execs have an outsized propensity to initiate deals, the professors found, but they’re also more likely to rebuff acquisition attempts by rivals, or to scrap deals that are already in progress.
Copyright © 2010-2018 by Arlene Weintraub
ChocoTheme by .css{mayo} | powered by WordPress
Entries (RSS) and Comments (RSS)